The GATSBY trial, which assessed the efficacy of T-DM1 in patients with HER2-positive GC, reported a median overall survival of 11.8 months in the T-DM1 group compared to 10.0 months in the paclitaxel chemotherapy group. The gene discussed is ERBB2; the disease is gastric cancer.